Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain
The screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and A...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Tropical Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2414-6366/8/7/373 |
| _version_ | 1827731698659360768 |
|---|---|
| author | Juan David Puyana Ortiz Andrea Carolina Garcés Rodríguez María Luisa Aznar Juan Espinosa Pereiro Adrián Sánchez-Montalvá Joan Martínez-Campreciós Nuria Saborit José Ángel Rodrigo-Pendás Guadalupe García Salgado Claudia Broto Cortes Nuria Serre Delcor Inés Oliveira Begoña Treviño Maruri Diana Pou Ciruelo Fernando Salvador Pau Bosch-Nicolau Irene Torrecilla-Martínez Ricardo Zules-Oña María Teresa Tórtola Fernández Israel Molina |
| author_facet | Juan David Puyana Ortiz Andrea Carolina Garcés Rodríguez María Luisa Aznar Juan Espinosa Pereiro Adrián Sánchez-Montalvá Joan Martínez-Campreciós Nuria Saborit José Ángel Rodrigo-Pendás Guadalupe García Salgado Claudia Broto Cortes Nuria Serre Delcor Inés Oliveira Begoña Treviño Maruri Diana Pou Ciruelo Fernando Salvador Pau Bosch-Nicolau Irene Torrecilla-Martínez Ricardo Zules-Oña María Teresa Tórtola Fernández Israel Molina |
| author_sort | Juan David Puyana Ortiz |
| collection | DOAJ |
| description | The screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and AEs for LTBI patients at two departments in Vall d’Hebron University Hospital in Barcelona, Spain. A retrospective study was conducted on all persons treated for LTBI between January 2018 and December 2020. Variables collected included demographics, the reason for LTBI screening and treatment initiation, AEs related to treatment, and treatment outcome. Out of 261 persons who initiated LTBI treatment, 145 (55.6%) were men, with a median age of 42.1 years. The indications for LTBI screening were household contact of a TB case in 96 (36.8%) persons, immunosuppressive treatment in 84 (32.2%), and recently arrived migrants from a country with high TB incidence in 81 (31.0%). Sixty-three (24.1%) persons presented at least one AE during treatment, and seven (2.7%) required definitive discontinuation of treatment. In the multivariate analysis, AE development was more frequent in those who started LTBI treatment due to immunosuppression. Overall, 226 (86.6%) completed treatment successfully. We concluded that LTBI screening and treatment groups had different risks for adverse events and treatment outcomes. Persons receiving immunosuppressive treatment were at higher risk of developing AEs, and recently arrived immigrants from countries with a high incidence of TB had greater LTFU. A person-centered adherence and AE management plan is recommended. |
| first_indexed | 2024-03-11T00:35:41Z |
| format | Article |
| id | doaj.art-e88222a814604376a17239087ede480d |
| institution | Directory Open Access Journal |
| issn | 2414-6366 |
| language | English |
| last_indexed | 2024-03-11T00:35:41Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Tropical Medicine and Infectious Disease |
| spelling | doaj.art-e88222a814604376a17239087ede480d2023-11-18T21:39:19ZengMDPI AGTropical Medicine and Infectious Disease2414-63662023-07-018737310.3390/tropicalmed8070373Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in SpainJuan David Puyana Ortiz0Andrea Carolina Garcés Rodríguez1María Luisa Aznar2Juan Espinosa Pereiro3Adrián Sánchez-Montalvá4Joan Martínez-Campreciós5Nuria Saborit6José Ángel Rodrigo-Pendás7Guadalupe García Salgado8Claudia Broto Cortes9Nuria Serre Delcor10Inés Oliveira11Begoña Treviño Maruri12Diana Pou Ciruelo13Fernando Salvador14Pau Bosch-Nicolau15Irene Torrecilla-Martínez16Ricardo Zules-Oña17María Teresa Tórtola Fernández18Israel Molina19International Health and Cooperation UAB, 08193 Barcelona, SpainMorales Meseguer University Hospital, 30008 Murcia, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainPreventive Medicine and Epidemiology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainPreventive Medicine and Epidemiology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainPreventive Medicine and Epidemiology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, SpainInternational Health Unit Vall d’Hebron-Drassanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08001 Barcelona, SpainThe screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and AEs for LTBI patients at two departments in Vall d’Hebron University Hospital in Barcelona, Spain. A retrospective study was conducted on all persons treated for LTBI between January 2018 and December 2020. Variables collected included demographics, the reason for LTBI screening and treatment initiation, AEs related to treatment, and treatment outcome. Out of 261 persons who initiated LTBI treatment, 145 (55.6%) were men, with a median age of 42.1 years. The indications for LTBI screening were household contact of a TB case in 96 (36.8%) persons, immunosuppressive treatment in 84 (32.2%), and recently arrived migrants from a country with high TB incidence in 81 (31.0%). Sixty-three (24.1%) persons presented at least one AE during treatment, and seven (2.7%) required definitive discontinuation of treatment. In the multivariate analysis, AE development was more frequent in those who started LTBI treatment due to immunosuppression. Overall, 226 (86.6%) completed treatment successfully. We concluded that LTBI screening and treatment groups had different risks for adverse events and treatment outcomes. Persons receiving immunosuppressive treatment were at higher risk of developing AEs, and recently arrived immigrants from countries with a high incidence of TB had greater LTFU. A person-centered adherence and AE management plan is recommended.https://www.mdpi.com/2414-6366/8/7/373<i>Mycobacterium tuberculosis</i>tuberculosis screeninglatent tuberculosis infectionadverse eventstoxicityadherence |
| spellingShingle | Juan David Puyana Ortiz Andrea Carolina Garcés Rodríguez María Luisa Aznar Juan Espinosa Pereiro Adrián Sánchez-Montalvá Joan Martínez-Campreciós Nuria Saborit José Ángel Rodrigo-Pendás Guadalupe García Salgado Claudia Broto Cortes Nuria Serre Delcor Inés Oliveira Begoña Treviño Maruri Diana Pou Ciruelo Fernando Salvador Pau Bosch-Nicolau Irene Torrecilla-Martínez Ricardo Zules-Oña María Teresa Tórtola Fernández Israel Molina Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain Tropical Medicine and Infectious Disease <i>Mycobacterium tuberculosis</i> tuberculosis screening latent tuberculosis infection adverse events toxicity adherence |
| title | Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain |
| title_full | Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain |
| title_fullStr | Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain |
| title_full_unstemmed | Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain |
| title_short | Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain |
| title_sort | adherence and toxicity during the treatment of latent tuberculous infection in a referral center in spain |
| topic | <i>Mycobacterium tuberculosis</i> tuberculosis screening latent tuberculosis infection adverse events toxicity adherence |
| url | https://www.mdpi.com/2414-6366/8/7/373 |
| work_keys_str_mv | AT juandavidpuyanaortiz adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT andreacarolinagarcesrodriguez adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT marialuisaaznar adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT juanespinosapereiro adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT adriansanchezmontalva adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT joanmartinezcamprecios adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT nuriasaborit adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT joseangelrodrigopendas adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT guadalupegarciasalgado adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT claudiabrotocortes adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT nuriaserredelcor adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT inesoliveira adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT begonatrevinomaruri adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT dianapouciruelo adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT fernandosalvador adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT pauboschnicolau adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT irenetorrecillamartinez adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT ricardozulesona adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT mariateresatortolafernandez adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain AT israelmolina adherenceandtoxicityduringthetreatmentoflatenttuberculousinfectioninareferralcenterinspain |